<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: For the laboratory diagnosis of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) we developed a biosensor with the ability to distinguish between disease-relevant anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta2GPI) autoantibodies (anti-beta2GPI) and pathogen-specific beta2GPI cross-reactive antibodies that occur transiently during <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We used a surface plasmon resonance (SPR) biosensor device </plain></SENT>
<SENT sid="2" pm="."><plain>For the detection of anti-beta2GPI in serum samples, affinity-purified human beta2GPI was covalently attached to a functionalized n-<z:chebi fb="0" ids="47908">alkanethiol</z:chebi> self-assembling monolayer on the biosensor chip </plain></SENT>
<SENT sid="3" pm="."><plain>After verifying the specificity of the biosensor system with a panel of monoclonal antibodies to beta2GPI, we analyzed sera from healthy donors and patients suffering from APS, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, or <z:e sem="disease" ids="C0085273" disease_type="Disease or Syndrome" abbrv="">parvovirus B19 infections</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The SPR results were compared with beta2GPI-specific ELISA </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Using the SPR biosensor, we recorded antigen binding curves with response levels in the range of 50-500, resonance units (RU) for anti-beta2GPI ELISA-positive APS patient sera </plain></SENT>
<SENT sid="6" pm="."><plain>The amplitudes of the <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (APL) responses in the biosensor correlated with the overall IgG and IgM anti-beta2GPI ELISA titers with a correlation coefficient of 0.87 </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, we observed immunoglobulin isotype-specific association and dissociation profiles for APL binding of different APS patient sera to the biosensor-immobilized beta2GPI </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast to APS patient samples, no significant anti-beta2GPI binding (response levels &lt;35 RU) was observed in samples from healthy individuals or from patients suffering from SLE, <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, or <z:e sem="disease" ids="C0085273" disease_type="Disease or Syndrome" abbrv="">parvovirus B19 infection</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The SPR biosensor system enables specific detection of APS-associated beta2GPI-reactive APL and differentiation from beta2GPI cross-reactive antibodies that occur frequently during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The established association/dissociation plot for anti-beta2GPI responses in APS patient sera gives additional information regarding the influence of anti-beta2GPI IgG and IgM isotype distribution </plain></SENT>
</text></document>